Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

DTC

Defence Therapeutics (DTC)

Defence Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:CSE:DTC
FechaHoraFuenteTítuloSímboloCompañía
16/02/202209:00InvestorsHub NewsWireDEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCERCSE:DTCDefence Therapeutics Inc
26/01/202207:49InvestorsHub NewsWireDefence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9CSE:DTCDefence Therapeutics Inc
30/11/202111:32InvestorsHub NewsWireDEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENTCSE:DTCDefence Therapeutics Inc
23/11/202107:24InvestorsHub NewsWireDEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCERCSE:DTCDefence Therapeutics Inc
09/11/202110:50InvestorsHub NewsWireDEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORSCSE:DTCDefence Therapeutics Inc
03/11/202107:11InvestorsHub NewsWireVACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITSCSE:DTCDefence Therapeutics Inc
13/10/202108:15InvestorsHub NewsWireDEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCERCSE:DTCDefence Therapeutics Inc
06/10/202108:32InvestorsHub NewsWireDEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMACSE:DTCDefence Therapeutics Inc
29/09/202107:30InvestorsHub NewsWireDEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCERCSE:DTCDefence Therapeutics Inc
20/09/202109:01InvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALSCSE:DTCDefence Therapeutics Inc
14/09/202107:13InvestorsHub NewsWireDEFENCE THERAPEUTICS SUCCESS IN TESTING IT'S COVID-19 ACCUVAC-PT001 VACCINE IN A NON-RODENT MODELCSE:DTCDefence Therapeutics Inc
07/09/202106:35InvestorsHub NewsWireDEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW HPV VACCINE INITIATEDCSE:DTCDefence Therapeutics Inc
01/09/202109:39InvestorsHub NewsWireThe vaccination specialist is about to become popularCSE:DTCDefence Therapeutics Inc
 Showing the most relevant articles for your search:CSE:DTC